--- title: "Barinthus Biotherapeutics 投资者警报：Kahn Swick & Foti, LLC 正在调查 Barinthus Biotherapeutics plc 的合并 - BRNS" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/285972713.md" description: "Kahn Swick & Foti, LLC 正在调查 Barinthus Biotherapeutics plc（纳斯达克代码：BRNS）与 Clywedog Therapeutics, Inc. 之间的拟议合并。合并后，Barinthus 的股东将仅持有新实体的 34.33%。该公司旨在评估合并过程对 Barinthus 股东的公平性和充分性。感兴趣的各方可以联系 KSF 管理合伙人 Lewis S. Kahn，获取有关与该交易相关的法律权利的更多信息" datetime: "2026-05-11T16:20:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285972713.md) - [en](https://longbridge.com/en/news/285972713.md) - [zh-HK](https://longbridge.com/zh-HK/news/285972713.md) --- # Barinthus Biotherapeutics 投资者警报：Kahn Swick & Foti, LLC 正在调查 Barinthus Biotherapeutics plc 的合并 - BRNS Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Barinthus Biotherapeutics plc (the “Company”) (NasdaqGM: BRNS) and Clywedog Therapeutics, Inc. Upon consummation of the transaction, Barinthus shareholders will own only 34.33% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Barinthus shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-brns/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner lewis.kahn@ksfcounsel.com 855-768-1857 1100 Poydras St., Suite 960 New Orleans, LA 70163 View source version on businesswire.com: https://www.businesswire.com/news/home/20260511755247/en/ ### 相关股票 - [BRNS.US](https://longbridge.com/zh-CN/quote/BRNS.US.md) - [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md) - [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md) - [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md) - [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md) - [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md) - [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md) - [IBBQ.US](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md) ## 相关资讯与研究 - [“搞钱”，才是 Revolution 千亿神话密码](https://longbridge.com/zh-CN/news/286888792.md) - [CAR-T 迎接新时代](https://longbridge.com/zh-CN/news/286999381.md) - [创胜集团医药-B 合作伙伴 INHIBRX 报告 OZEKIBART 的 CRC 最新积极数据并宣布就治疗软骨肉瘤提交美国 BLA 申请](https://longbridge.com/zh-CN/news/287126678.md) - [Tevogen Bio Q1 运营亏损收窄 48%，推进 AI 平台与细胞疗法管线](https://longbridge.com/zh-CN/news/287086570.md) - [制药巨头集体拥抱 AI 智能体：百时美施贵宝向 3 万员工推广 Claude](https://longbridge.com/zh-CN/news/287074661.md)